Search Articles
PHOENIX – Insys Therapeutics goosed its share price with false and deceptive statements and unethical ads about its Subsys drug, and the price dropped by 17% in a day when the truth came out, shareholders claim in a federal class action.
Categories /
Uncategorized
Subscribe to our free newsletters
Our weekly newsletter Closing Arguments offers the latest about ongoing trials, major litigation and rulings in courthouses around the U.S. and the world, while the monthly Under the Lights dishes the legal dirt from Hollywood, sports, Big Tech and the arts.